Xenon Pharmaceuticals annual operating margin
2012
2013
2014
2015
2016
2017
2019
2020
2021
2022
2025
Xenon Pharmaceuticals's operating margin was −4,974.27% for fiscal 2025.
View full Xenon Pharmaceuticals company overview| Fiscal year | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −4,974.27% | −3605.36 pp |
| 2022 | 2022-12-31 | −1,368.91% | −940.46 pp |
| 2021 | 2021-12-31 | −428.45% | −331.14 pp |
| 2020 | 2020-12-31 | −97.31% | +529.71 pp |
| 2019 | 2019-12-31 | −627.02% | +9847.26 pp |
| 2017 | 2017-12-31 | −10,474.28% | −9097.85 pp |
| 2016 | 2016-12-31 | −1,376.43% | −1316.33 pp |
| 2015 | 2015-12-31 | −60.10% | −99.24 pp |
| 2014 | 2014-12-31 | 39.15% | +3.64 pp |
| 2013 | 2013-12-31 | 35.50% | +57.54 pp |
| 2012 | 2012-12-31 | −22.04% | — |
| Fiscal quarter | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| Q1 2025 | 2025-03-31 | −969.84% | −305.19 pp |
| Q3 2022 | 2022-09-30 | −28,884.85% | −28692.85 pp |
| Q2 2022 | 2022-06-30 | −5,655.78% | −4641.45 pp |
| Q1 2022 | 2022-03-31 | −198.14% | +170.35 pp |
| Q4 2021 | 2021-12-31 | −664.65% | −413.72 pp |
| Q3 2021 | 2021-09-30 | −192.00% | −44.01 pp |
| Q2 2021 | 2021-06-30 | −1,014.34% | −1009.51 pp |
| Q1 2021 | 2021-03-31 | −368.49% | −255.00 pp |
| Q4 2020 | 2020-12-31 | −250.93% | +4.81 pp |
| Q3 2020 | 2020-09-30 | −147.99% | +50170.76 pp |
| Q2 2020 | 2020-06-30 | −4.83% | +3269.42 pp |
| Q1 2020 | 2020-03-31 | −113.49% | +52506.51 pp |
| Q3 2019 | 2019-09-30 | −255.74% | +49663.01 pp |
| Q4 2017 | 2017-12-31 | −50,318.75% | −48866.09 pp |
| Q3 2017 | 2017-09-30 | −3,274.24% | −1499.18 pp |
| Q2 2017 | 2017-06-30 | −52,620.00% | −51078.60 pp |
| Q1 2017 | 2017-03-31 | −49,918.75% | −48977.32 pp |
| Q4 2016 | 2016-12-31 | −1,452.66% | −1372.00 pp |
| Q3 2016 | 2016-09-30 | −1,775.06% | −1755.96 pp |
| Q2 2016 | 2016-06-30 | −1,541.40% | −1546.32 pp |
| Q1 2016 | 2016-03-31 | −941.43% | −788.39 pp |
| Q4 2015 | 2015-12-31 | −80.66% | −146.31 pp |
| Q3 2015 | 2015-09-30 | −19.10% | −45.11 pp |
| Q2 2015 | 2015-06-30 | 4.92% | −55.51 pp |
| Q1 2015 | 2015-03-31 | −153.04% | — |
| Q3 2014 | 2014-09-30 | 65.65% | — |
| Q2 2014 | 2014-06-30 | 26.01% | — |
| Q3 2013 | 2013-09-30 | 60.43% | — |
Over the last five reported fiscal years, Xenon Pharmaceuticals's operating margin increased from −10,474.28% to −4,974.27%, a change of +5500.01 percentage points. The latest reported quarter, Q1 2025, shows −969.84%.
Operating margin measures the percentage of revenue left after operating costs and expenses. It shows how much operating profit a company generates from each dollar of revenue.
TickerStat calculates operating margin as SEC-reported operating income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Xenon Pharmaceuticals filings at SEC.gov ↗